RE:What nextWhile it is likely a done deal, paying off the convert shouild be mentioned as it is a very key item. After that is completed, cash is going to look even skimpier than it already does. So, one wonders what might be the plan on that front - I imagine they want to get the AGM concluded befoer doing anything on that which might upset shareholders. Hopefully, it can be addressed via partnership cash versus stock sales at such low prices. But we know they sold shares at low prices in the Fall (admittedly not this low) via the ATM.
They need to generate sales and cut costs to become profitable onthhe legacy drugs and they need to get interesting results from TH-1902. Those are the things that have the highest probability of generating upward movement in the stock price. Both seem achievable but it will take time.
Trogarzon wrote: So next is the Th1902 FDA resubmit, than Trogarzo IM data, than Egrifta Human factor study to meet FDA requirements to sell Egrifta onward. What else apart from those exciting milestone do we have to excite buyers. Partners, deals, what else. This feels like a fishing trip with no fish. Just a boat tour in a boat without a captain on it's way to nowhere.